HDL Therapeutics competitorsClear all

HDL Therapeutics's top competitors include BioCardia, FIRE1, ElectroCore and ReShape Lifesciences.
HDL Therapeutics
HDL Therapeutics
HDL Therapeutics is a company that develops medical devices for the treatment of coronary atherosclerosis.
BioCardia
BioCardia
BioCardia is a clinical-stage regenerative medicine company.
FIRE1
FIRE1
FIRE1 focuses on developing novel remote monitoring devices.
ElectroCore
ElectroCore
ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.
ReShape Lifesciences
ReShape Lifesciences
ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.
Founding Date
Founding Date
2009
Founding Date
2002
Founding Date
N/A
Founding Date
2005
Founding Date
2002
Type
Type
Private
Type
Private
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Vero Beach, US HQ
Locations
San Carlos, US HQ
Locations
Glasnevin, IE HQ
Dublin, IE
Locations
Bernards, US HQ
Parksville, CA
Geretsried, DE
Hamburg, DE
Yeadon, GB
Locations
San Clemente, US HQ
San Clemente, US
Employees
Employees
7
Employees
2713% increase
Employees
36
Employees
5144% decrease
Employees
4348% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
120.9 m
Valuation ($)
38.3 m
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
1.8 k
Twitter followers
402
Alexa Website Rank
Alexa Website Rank
222186
Alexa Website Rank
257929
Alexa Website Rank
591409
Alexa Website Rank
281232
Alexa Website Rank
421170

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$710k (FY, 2019)
Revenue (est.)
N/A
Revenue (est.)
$2.4m (FY, 2019)
Revenue (est.)
$15.1m (FY, 2019)
Cost of goods
Cost of goods
N/A
Cost of goods
$358k (FY, 2019)
Cost of goods
N/A
Cost of goods
$1.2m (FY, 2019)
Cost of goods
$5.8m (FY, 2019)
Gross profit
Gross profit
N/A
Gross profit
$352k (FY, 2019)
Gross profit
N/A
Gross profit
$1.2m (FY, 2019)
Gross profit
$9.3m (FY, 2019)
Net income
Net income
N/A
Net income
($14.7m) (FY, 2019)
Net income
N/A
Net income
($45.1m) (FY, 2019)
Net income
($74.2m) (FY, 2019)

Funding

Latest funding round
Latest funding round
$ 3m (over 1 year ago)
Latest funding round
$ 7.4m (over 12 years ago)
Latest funding round
$ 7.5m (almost 5 years ago)
Latest funding round
N/A
Latest funding round
N/A
Total funding raised
Total funding raised
$ 7.4m
Total funding raised
N/A
Total funding raised
$ 7.5m
Total funding raised
$ 127m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

BioCardia
HQ
San Carlos, US
Employees
27↑ 13% increase

BioCardia is a clinical-stage regenerative medicine company.

View company
FIRE1
HQ
Glasnevin, IE
Employees
36

FIRE1 focuses on developing novel remote monitoring devices.

View company
ElectroCore
HQ
Bernards, US
Employees
51↓ 44% decrease

ElectroCore develops neuromodulation therapies for the non-invasive treatment of diseases and disorders.

View company
ReShape Lifesciences
HQ
San Clemente, US
Employees
43↓ 48% decrease

ReShape Lifesciences, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders.

View company